Off-label uses of biologics in dermatology: interferon and intravenous immunoglobulin (part 1 of 2).

@article{Smith2007OfflabelUO,
  title={Off-label uses of biologics in dermatology: interferon and intravenous immunoglobulin (part 1 of 2).},
  author={David I Smith and P M Shivakumara Swamy and Michael P Heffernan},
  journal={Journal of the American Academy of Dermatology},
  year={2007},
  volume={56 1},
  pages={e1-54}
}
The introduction of a number of biologic therapies into the market has revolutionized the practice of dermatology. These therapies include interferons, intravenous immunoglobulin, infliximab, adalimumab, etanercept, efalizumab, alefacept, and rituximab. Most dermatologists are familiar with the Food and Drug Administration-approved indications of these medications. However, numerous off-label uses have evolved. As part 1 of a 2-part series, this article will review the literature regarding the… CONTINUE READING